Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still’s disease: a single-center retrospective study
Tocilizumab combined with short-term high-dose glucocorticoids may provide rapid disease control and facilitate glucocorticoid tapering in AOSD. More prospective studies are needed to confirm these findings.
Authors
- Ai-xia Niu
- Yongjun He (ORCID: https://orcid.org/0000-0002-2031-4539)
- Bo Liu (ORCID: https://orcid.org/0000-0003-1685-7968)
- Qi-Bin Yang
- Li-Xuan Zhou
- Yan-Ping Lei
- Shi-Lei Zhong
Institutions
- North Sichuan Medical University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1732826
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China